Korea Stocks, page 28 of 36 — 24 articles published 2026-07-13 ~ 2026-07-14.
Jeisys Medical (287410) 2026 stock outlook. A deep qualitative look at its RF and HIFU energy-based devices, the recurring consumable-tip revenue model, POTENZA export momentum, the three-way fight with Classys and Wontech, ownership and M&A risk, and the metrics that actually move this KOSDAQ aesthetic name.
T'way Air (KOSPI 091810) 2026 stock outlook. An in-depth look at why a Korean low-cost carrier is flying long-haul to Europe and Australia, the Korean Air-Asiana merger windfall, the Daemyung Sono ownership fight, and the fuel, FX, and aircraft-lease risks that define the thesis.
Hyosung TNC (298020) 2026 stock outlook. A deep look at CREORA spandex global #1 pricing power, bio-based spandex and regen recycled-fiber premium, versus PTMEG/BDO raw-material costs, Chinese capacity additions, and apparel-demand cycles for the US investor.
DL E&C (KOSPI 375500) 2026 stock outlook. A deep qualitative look at the ACRO and e-Pyeonhansesang housing brands, cost-to-completion and real-estate PF risk, and the pivot into overseas plant EPC, carbon capture (CCUS), hydrogen, and SMR, plus the low-valuation and shareholder-return debate.
Korea Investment Holdings (071050) stock outlook for 2026: how Korea Investment & Securities' brokerage, IB, and WM engine works alongside its Kakao Bank stake, the holding-company discount, and rate and volume cycle risk.
Pulmuone (KOSPI 017810) 2026 stock analysis: the #1 Korean fresh-food brand in tofu, bean sprouts, and fresh noodles, its structurally thin operating margins, imported-soybean and FX cost pressure, the Nasoya US tofu turnaround, plant-based expansion, and how it stacks up against CJ CheilJedang, Ottogi, Nongshim, and Daesang.
S-1 Corporation (012750) 2026 stock outlook: Korea's largest physical security operator, its subscription-style rental revenue moat, the margin drag from facility management, AI video security and unmanned-store upside, and the SK Shieldus rivalry.
Hana Tour (039130) 2026 stock outlook. A qualitative deep dive into Korea's top travel wholesaler: its nationwide agency-network moat, the post-Covid ownership shift to private equity firm IMM PE, mounting OTA competition, won/dollar exposure, and jet-fuel-linked airline capacity risk.
RFHIC (KOSDAQ 218410) 2026 stock outlook. A deep qualitative look at its GaN RF transistor and power amplifier business tied to 5G base stations, customer concentration in Samsung and Nokia, the pivot into defense RF and SiC power semiconductors, and competition from Wolfspeed, Qorvo and MACOM.
A qualitative deep dive into the Dongkuk Steel (460860) stock outlook for 2026, covering the 2023 spin-off from holding company Dongkuk Holdings and sister firm Dongkuk CM, its plate and section-steel product mix, electric arc furnace economics, construction-cycle and Chinese oversupply risk, post-split capital allocation, and how Korea-stock taxation works for foreign investors.
Dong-A ST (KOSPI 170900) 2026 stock outlook. A deep look at the IMULDOSA ustekinumab biosimilar with US and EU approvals, Intas and Accord licensing, the Growtropin growth-hormone franchise, diabetes and obesity pipeline, Korean drug-price pressure, and how it stacks up against Celltrion, Samsung Bioepis, Chong Kun Dang and Yuhan.
A qualitative 2026 outlook on Dongwha Pharmaceutical (KRX: 000020), Korea's oldest listed drugmaker. We unpack the century-old Gaswhalmyeongsu, Fucidin and Norumo OTC franchise, the generics and licensed-drug prescription business, its early-stage new-drug and biotech push, peer positioning, risks, and how international investors should size and tax a Korean small-cap cash cow.
SOOP (formerly AfreecaTV, KOSDAQ 067160) stock outlook for 2026. A qualitative deep dive into the high-margin Star Balloon gifting economy, sticky live communities, global SOOP expansion, the Chzzk competitive threat, top-streamer concentration, and gifting regulation risk.
Lotte Energy Materials (020150) stock outlook 2026. A qualitative deep dive into the former Iljin Materials, the world-class ultra-thin battery copper foil (Elecfoil) maker's moat, chasm-driven utilization pressure, Chinese oversupply, and Europe/US expansion risk.
SeAH Steel (KOSPI 306200) 2026 analysis for US investors: welded steel pipe and OCTG exports tied to US drilling and oil price, Section 232 quota and anti-dumping risk, the offshore-wind monopile growth leg, steel-spread volatility, and how it stacks up against Tenaris, Vallourec, Husteel and Nexteel.
Hansae Co. (105630) 2026 stock outlook: the knitwear OEM behind Nike, Gap, and Target, its Vietnam-Nicaragua-Indonesia production diversification, US tariff exposure, brand inventory-cycle risk, and how global investors can access this Korea-listed apparel manufacturer.
Hansol Chemical (014680) 2026 stock analysis: dominance in high-purity hydrogen peroxide for semiconductor and display fabs, QD display materials, silicon anode and battery binder growth bets, customer concentration on Samsung and SK hynix, and memory capex cycle exposure.
Dongwon Industries (KRX: 006040) 2026 stock outlook: a deep-sea tuna fishing fleet feeding StarKist, America's top canned-tuna brand, layered with a mid-tier holding structure over Dongwon Group's food and logistics affiliates. We unpack the moat, the price-fixing history, FX exposure, and the holding-company discount.
KSS Line (044450) 2026 stock analysis: how long-term contracts of affreightment (COA) stabilize cash flow for this Korean LPG/LNG/ammonia gas carrier operator, the ammonia-fuel optionality, and the newbuild price and charter-rate cycle risks investors need to weigh.
SD Biosensor (KOSPI 137310) 2026 stock analysis: normalizing revenue after the COVID rapid-test boom, the Meridian Bioscience acquisition, a large cash pile and capital allocation, POCT and molecular diagnostics diversification, and the Abbott/Roche competitive landscape.
Cosmo Advanced Materials (Cosmo AM&T, KRX 005070) 2026 stock outlook: a qualitative deep dive into its high-nickel NCM cathode growth story, the steady cash flow of its MLCC release and toner film business, EV demand chasm exposure, lithium and nickel price pass-through, heavy capex financing risk, and how it stacks up against larger cathode makers like EcoPro and L&F.
A qualitative 2026 stock outlook for Celltrion Pharm (KOSDAQ 068760): its role distributing the Celltrion group's biosimilars in Korea, the Cheongju chemical-drug business, group governance and related-party risk, a rich valuation versus earnings, and dependence on the parent.
A qualitative 2026 outlook on Dong Kook Pharmaceutical (KOSPI 086450): the Madecassol and Insadol OTC brand moat, prescription-drug stability, Centellian24 cosmetics and health-functional-food growth, home-shopping channel dependence, drug-pricing risk, and the dividend case.
Duksan Neolux (KOSDAQ 213420) 2026 stock outlook. A qualitative deep-dive into its OLED organic materials business (HTL, Red Host, Red Prime), the qualification moat as a core Samsung Display supplier, upside from OLED expansion into IT, foldables and automotive, plus customer-concentration and China panel-maker risks.